LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of investors of Trinity Biotech plc (“Trinity” or the “Company”) (NASDAQ: TRIB) concerning the Company and its officers’ possible violations of federal securities laws.
Trinity acquires, develops, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market.
The investigation concerns Trinity’s October 4, 2016 announcement that the Company was withdrawing its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer on the recommendation of the U.S. Food and Drug Administration. On news of the withdrawal, Trinity’s share price fell over 50% to close at just $6.46 per share on October 4, 2016, thereby injuring investors.
If you purchased Trinity securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at http://glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.